Little is known about the relative harms of edible and inhalable cannabis products.
C
olorado saw an increase in cannabis use after liberalization of medical cannabis in 2009 (1) and recreational cannabis in 2014 (2) . Increased availability and use of cannabis in Colorado has led to an increase in emergency department (ED) visits associated with the drug (3) . In 2014, the Marijuana Enforcement Division began collecting and reporting data on cannabis product sales. Cannabis is most often purchased in flower form for smoking; edible cannabis accounts for only 0.3% of the weight of tetrahydrocannabinol (THC) in total cannabis product sales (4) . According to the Colorado Behavioral Risk Factor Surveillance System, 40.4% of marijuana users report smoking cannabis only, whereas 3.6% report using edible cannabis products only (5) . The remainder use a combination of the products.
Despite edible cannabis products accounting for a small proportion of the total number of cannabis products sold and used, they frequently contribute to ED visits and may be more toxic than inhalable products. This is supported by increasing numbers of adverse events associated with edible cannabis being reported to poison centers (6) , as well as troubling anecdotes of users (7) (8) (9) . In Colorado, the only deaths definitively associated with cannabis use involved edible products (10 -12) , which also supports increased toxicity with this route of exposure. However, whether these anecdotal reports by adult users (9) and limited poison center data (13) truly show increased toxicity of edible cannabis compared with inhalable cannabis is unclear. The objective of this study was to describe and compare adult ED visits associated with edible and inhalable cannabis products.
METHODS

Study Design and Population
This was a retrospective observational study based on chart review of patients presenting to the UCHealth University of Colorado Hospital Emergency Department (UCHED). The UCHED serves an urban academic hospital with approximately 100 000 visits per year. More than 97% of patients seen in the UCHED are aged 18 years or older.
All UCHED visits from 1 January 2012 through 31 December 2016 were eligible for inclusion. Visits that contained an International Classification of Diseases, Ninth or 10th Revision, Clinical Modification (ICD-9-CM or ICD-10-CM), code consistent with cannabis exposure were manually reviewed to collect variables of interest (Appendix Table, available at Annals.org). The study protocol was approved by the local institutional review board.
Study Participants and Coding
Adults with an ED visit containing a cannabisrelated ICD-9-CM or ICD-10-CM code were included. Assessment of cannabis use is included in the drug use section of the standard nursing assessment questionnaire administered to patients seen at the UCHED and in the clinical notes of the medical providers. A visit was considered at least partially attributable to cannabis if 1 or more of the following criteria were met: 1) the ED provider identified cannabis as likely precipitating or contributing to the condition, 2) the patient was admitted to the hospital and the inpatient provider identified cannabis as likely precipitating or contributing to the condition, or 3) the urine toxicologic screening result was positive and there was a documented temporal relationship (within approximately 24 hours) with cannabis exposure and there was a condition or an event known to be associated with cannabis use (for example, motor vehicle collision or acute panic attack). Patients were considered pregnant if they had a positive urine pregnancy test result or on the basis of clinician note review when no pregnancy test was performed.
Measurements
Visits to the UCHED with cannabis-related ICD-9-CM or ICD-10-CM codes were manually abstracted by 4 trained research assistants who were blinded to the study hypothesis. Research assistants coded whether the visit was at least partially attributable to cannabis, the route of exposure, the dose (when available), the clinical symptoms, and the presenting symptoms. Clinical and presenting symptoms were not mutually exclusive. When the route of exposure was not documented, it was as- The research assistants were trained in chart abstraction using 50 UCHED charts with cannabis-related ICD-9-CM and ICD-10-CM codes selected from the study period. Charts were abstracted by a medical toxicologist and one of the research assistants. Discrepancies in coding were determined with regard to attribution of the visit to cannabis, clinical symptoms, route of exposure, and reported dose. The research assistants were retrained on discrepancies, and an additional 250 charts were then reviewed by the medical toxicologist to determine accuracy. The medical toxicologist abstracted a random sample of 10% of all charts reviewed by the research assistants, and the statistic was calculated to determine interrater reliability. Double abstraction was performed on 1111 visits in the ICD codegenerated data set. Visits with questionable attribution to cannabis were arbitrated by the medical toxicologist. A sensitivity analysis was performed using 1% of all UCHED charts to ensure adequate capture of cannabisrelated visits using the ICD-9-CM and ICD-10-CM code search strategy.
Statistical Analysis
Descriptive statistics were used to characterize categorical variables in the overall population and in the subpopulations with cannabis-attributable and edible cannabis-attributable visits. Differences among the groups were evaluated using a 2 test. Absolute differences in clinical symptoms (with 95% CIs) were calculated as the percentage in the edible group minus the percentage in the inhalable group. Length of stay was summarized in both groups. Data analysis was performed using SAS, version 9.4 (SAS Institute).
We also compared the proportions of cannabisattributable visits by route of exposure (edible vs. inhalable) with the corresponding proportions of cannabis sales in the state. For this analysis, we summarized cannabis product sales data for Colorado and converted to kilograms of THC. We assumed THC content of 20% per kilogram of flower sold for inhalable cannabis and 10 mg of THC for each unit sold for edible cannabis. Assuming a 1:9 ratio for edible versus inhaled exposures, we calculated that a sample size of 2000 would provide enough data to reliably estimate a 5-fold increased rate of ED visits for edible versus inhaled exposure.
Role of the Funding Source
The Colorado Department of Public Health and Environment (CDPHE) funded this study through a competitive grant program. The CDPHE was not involved in study design, analysis, data interpretation, or dissemination of these findings.
RESULTS
There were 449 031 eligible visits to the UCHED during the study period. Cannabis-related ICD-9-CM or ICD-10-CM codes were present in 9973 visits ( Table 1) , and 2567 visits (25.7%) were deemed at least partially attributable to cannabis. Among these, the route of exposure was available in 2432 (94.7%). Edible ingestion was reported in 238 visits (9.3%), and exposure in the remainder was considered to be via inhalation (2194 were documented as such, and 135 had insufficient documentation) ( Figure 1 ). The frequency of visits attributable to inhalable and edible cannabis increased each year during the study period ( Figure 2 ). The dose was available in only 130 records (5.1%). Pregnant women accounted for fewer than 2% of patients with a cannabis-attributable visit (n = 46).
Reasons for Cannabis-Attributable ED Visits
Gastrointestinal symptoms, including cannabinoid hyperemesis syndrome, were the most common reason among patients with cannabis-attributable visits (n = 788 [30.7%] Acute Illness Associated With Cannabis Use, by Route of Exposure ORIGINAL RESEARCH chronic disease; and 100 (15.8%) were for chronic psychiatric conditions, such as depression, schizophrenia, or psychosis ( Table 2) .
Comparison of Visits Attributable to Inhalable Versus Edible Cannabis
Patients with visits attributed to edible cannabis were similar in age to those with visits attributed to inhalable cannabis; however, they were more likely to be female (51.3% vs. 33.1%; P < 0.001), more likely to live outside Colorado (40.8% vs. 6.6%; P < 0.001), and less likely to be admitted to the hospital (18.9% vs. 32.9%; P < 0.001). Length of stay was longer for visits attributable to inhalable cannabis (median, 3 hours [range, 0 to 121 hours] vs. 2 hours [range, 1 to 54 hours]).
Clinical symptoms for cannabis-attributable visits varied between the inhaled and edible exposure groups. Gastrointestinal symptoms were more common in patients exposed to inhalable compared with edible cannabis; 18.0% versus 8.4% had cannabinoid hyperemesis syndrome (mean difference, 9.6 percentage points [95% CI, 5.7 to 13.5 percentage points]; P < 0.001). Although there was no difference in the frequency of overall psychiatric-related visits between groups, visits related to acute psychiatric symptoms were more common in patients with edible exposures (18.0% vs. 10.9%; mean difference, 7.1 percentage points [CI, 2.1 to 12.1 percentage points]; P < 0.001). Visits due to cardiovascular symptoms were also more common in patients exposed to edible products (8.0% vs. 3.1%; P < 0.001). Severe adverse cardiovascular events, including myocardial infarction and ventricular dysrhythmia, occurred in both groups.
Chart Review Sensitivity and Interrater Reliability
We reviewed 4800 random ED records from the 449 031 overall visits from the study period. During 2012 to 2014, there were no records containing a mention of cannabis that were not included in our ICD-9-CM-generated data set. In 2015 and 2016, there were 26 records with a mention of cannabis exposure that were not captured by our search criteria (0.01% of total records). These charts were all in the subset of visits in which ICD-10-CM codes were used and represented polypharmacy ingestion cases with no identified temporal relationship with cannabis use and no urine toxicologic screening. The cannabis references were medical shorthand notation (for example, "+cann" or "+pot") identified in consulting physician notes, and the exposure was not documented by the primary medical team caring for the patient. None of these cases were considered cannabis-attributable by our definition. The interrater reliability for abstracted data was good ( = 0.79 [CI, 0.75 to 0.83]).
Colorado Sales Data by Route of Exposure
Sales data showed that the unadjusted quantity of THC sold as both inhalable products and edible products increased between 2014 and 2016 in Colorado ( Table 3) . There was 309 times more THC sold in flower form, the primary product sold for inhalation, compared with edible products (range, 279 to 325) over this period. During the same period, 219 ED visits were attributable to edible exposure and 1819 to inhaled exposure. Thus, an estimated 10.7% of cannabisattributable ED visits between 2014 and 2016 were due to edible cannabis.
DISCUSSION
This study involving nearly 10 000 cannabis-related ED visits with manual reconciliation of the role cannabis played in each visit showed that, although less frequent overall, edible products lead to more acute psychiatric events and cardiovascular symptoms than inhaled exposure. The high frequency of visits and the greater likelihood of hospital admission associated with inhalable products suggest that user education about the adverse health effects of inhalable cannabis may have the greatest effect on public health.
A PubMed literature search using the terms cannabis edible OR cannabis emergency on 8 November 2018 found 446 articles. In addition, we examined the systematic literature review report of the CDPHE's Retail Marijuana Public Health Advisory Committee, which is updated quarterly, on 22 October 2018. These articles suggest that ED visits associated with cannabis use are increasing (3, 14) . Edible products are a major source of unintentional cannabis exposures in children, but the differences in health care visits associated with edible versus inhalable cannabis in adults have not been systematically examined (15) (16) (17) . It has become clear that cannabis is associated with acute psychiatric illness (18 -20) , and this has led to more ED visits that are at least partially attributable to cannabis, although these studies did not stratify visits by route of exposure. Similarly, a study that examined the National Inpatient Sample found that admissions associated with cannabis had a high proportion of psychiatric and cardiovascular symptoms, although these visits also were not stratified by route of exposure (21) . The kinetics of absorption, onset, and duration of action of edible products may be well suited for medical indications but are not ideal for recreational use, in which the user hopes to feel the effects rapidly. Inhalable cannabis results in clinical effects within 10 minutes, peak blood concentrations occur within 30 to 90 minutes, and clearance is complete within 4 hours. Oral THC does not reach significant blood concentration until at least 30 minutes, with a peak at approximately 3 hours and clearance approximately 12 hours after ingestion (22) . Users report longer-lasting effects with edible products than with smoking or vaping (8); they also report more intense effects and unpleasant psychiatric symptoms (9) . These factors may lead to more severe clinical manifestations; death has been associated with use of edible products, as in the cases of a man who jumped from a balcony after consuming an edible product (11), a woman who was killed by her husband after he ingested an edible product (10) , and a man who died by suicide at a ski resort after eating an edible product (12) .
Hospital admission was more common in the cohort with visits attributable to inhalable cannabis. This seemed to be driven by admission of patients with cannabinoid hyperemesis syndrome, which is far more common among patients with inhaled exposure. The larger proportion of acute psychiatric visits associated with edible exposure is troubling given the capacity of THC to cause or exacerbate psychosis (20, (23) (24) (25) and the risk for violent behaviors linked to cannabisassociated psychosis (26, 27) . The association of cardiovascular visits with edible exposure is also concerning. Cannabis is now recognized as a risk factor for adverse cardiovascular events (28, 29) , and the increased rate of visits associated with edible products seems to have translated to a higher proportion of cardiovascular events in such visits.
Other studies using public health data (30), administrative hospital data sets (19) , poison center data (15, 17) , and retrospective designs (31, 32) have shown increased ED visits associated with cannabis use. These studies did not use chart review to assess validity of diagnoses or symptoms. Despite its strengths, our study has several important limitations. It used a retrospective design with exposure data captured largely through self-report. There was no comparative community-based exposure cohort. Patients presenting to the ED clearly differ from the overall population of cannabis users, most of whom may use cannabis with no adverse effects. A prospective cohort of users and nonusers is necessary to determine the true rates of cannabis-attributable visits in the user population. We could not verify doses, and ingested doses may have been larger than inhaled doses. However, the dose was documented in 80 visits attributable to edible exposure, and only 19 were 50 mg or higher. We were surprised by the low dose of edible products reported by these patients considering that a typical joint in Colorado contains approximately 100 mg of THC. In addition, route of exposure was captured from the medical record and was presumed to be inhalation when it was not documented. This could have biased the analyses toward greater toxicity in the cohort with inhaled exposure, which further emphasizes our finding that edible products have greater toxicity per unit of cannabis sold. Finally, the UCHED has the second most visits per year in the state and is located in an area with high cannabis availability. These factors likely increase the rates of cannabis-attributable ED visits at this hospital.
Our data suggest an interesting relationship between route of cannabis exposure and ED visits. Although edible cannabis accounted for only 0.32% of total cannabis sales (in kilograms of THC) from 2014 to 2016, 10.7% of cannabis-attributable visits at the UCHED in this period were due to edible cannabis. If inhalable and edible cannabis were equally toxic and resulted in the same number of ED visits, we would expect that 0.3% of cannabis-attributable visits would be due to use of edible products. The observed proportion of cannabis-attributable visits with edible exposure was about 33 times higher than expected (10.7% vs. 0.32%) if both routes of exposure were equally toxic. However, there are limitations in using state-level sales data to infer ED visit rates, and careful interpretation of the results is required. First, we made assumptions about the THC content of the flower and edible products based on the average known THC concentration in Colorado products. Furthermore, we compared chart (17), and user naiveness (7, 35) . These findings should be considered carefully in states considering legalization of recreational cannabis. Some have argued for stricter state regulations on edible products, with pediatric exposures as the primary supporting evidence (36). It may be best to limit edible products to medical indications in order to minimize pediatric exposures and mitigate the excessive rate of adult ED visits associated with these products. At the very least, users must be educated about the delayed kinetic profile and the increased risk for acute psychiatric and adverse cardiovascular events associated with edible ingestion. As suggested by the American College of Clinical Pharmacology (37), the U.S. Food and Drug Administration should strongly consider increased oversight of these products in order to standardize packaging, dosing, warnings, and user education. Minimization of heavy cannabis use may lead to fewer ED visits and hospital admissions related to cannabinoid hyperemesis syndrome. Education of users about the adverse health effects of cannabis use may have the greatest effect on public health.
In conclusion, inhalable cannabis results in a higher frequency of cannabis-attributable ED visits, although acute psychiatric events and cardiovascular symptoms are more common with edible exposure. Future studies that examine cannabis-attributable ED visits should be stratified by route of exposure and should account for population exposure to inhalable and edible products. 
